Jerome Samir

Jerome Samir

Auto-generated profile, based on publicly available information

Jerome Samir

School of Medical Sciences, UNSW Sydney, Sydney, NSW 2052, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
LSLucy C. Sullivan
Lucy C. Sullivan
TNThi Hoang Oanh Nguyen
Thi Hoang Oanh Nguyen
CHChristopher M. Harpur
Christopher M. Harpur
SSSanda Stankovic
Sanda Stankovic
AKAbbie R. Kanagarajah
Abbie R. Kanagarajah
ABAndrew G. Brooks
Andrew G. Brooks
Human cytomegalovirus (CMV) infection can stimulate robust human leukocyte antigen (HLA)–E–restricted CD8+ T cell responses. These T cells recognize a peptide from UL40, which differs by as little as a single methyl group from self-peptides that also bind HLA-E, challenging their capacity to avoid self-reactivity. Unexpectedly, we showed that the UL40/HLA-E T cell receptor (TCR) repertoire included TCRs that had high affinities for HLA-E/self-peptide. However, paradoxically, lower cytokine responses were observed from UL40/HLA-E T cells bearing TCRs with high affinity for HLA-E. RNA sequencing and flow cytometric analysis revealed that these T cells were marked by the expression of inhibitory natural killer cell receptors (NKRs) KIR2DL1 and KIR2DL2/L3. On the other hand, UL40/HLA-E T cells bearing lower-affinity TCRs expressed the activating receptor NKG2C. Activation of T cells bearing higher-affinity TCRs was regulated by the interaction between KIR2D receptors and HLA-C. These findings identify a role for NKR signaling in regulating self/non-self discrimination by HLA-E–restricted T cells, allowing for antiviral responses while avoiding contemporaneous self-reactivity.

14 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMandeep Singh
Mandeep Singh
RLRaymond H. Y. Louie
Raymond H. Y. Louie
JSJerome Samir
Jerome Samir
MFMatthew Field
Matthew Field
CMClaire Milthorpe
Claire Milthorpe
FLFabio Luciani
Fabio Luciani
Intestinal inflammation continues in a subset of patients with celiac disease despite a gluten-free diet. Here, by applying multi-omic single-cell analysis to duodenal biopsies, we found that low-grade malignancies with lymphoma driver mutations in patients with refractory celiac disease type 2 (RCD2) are comprised by surface CD3-negative (sCD3 − ) lymphocytes stalled at an innate lymphoid cell (ILC)–progenitor T cell stage undergoing extensive TRA , TRB , and TRD TCR recombination. In people with refractory celiac disease type 1 (RCD1), a disease currently lacking explanation, we identified sCD3 + T cells with lymphoma driver mutations in 6 of 10 individuals with RCD1 and in one of the patients with active, recently diagnosed celiac disease. Furthermore, the mutant T cells formed large TCRαβ clones and displayed inflammatory and cytotoxic molecular profiles. Thus, accumulation of lymphoma driver–mutated T cells and sCD3 − progenitors may contribute to chronic, nonresponsive celiac disease.

14 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LGLuca Ghita
Luca Ghita
ZYZhiyuan Yao
Zhiyuan Yao
YXYike Xie
Yike Xie
VDVeronica Duran
Veronica Duran
HChalise busra cagirici
halise busra cagirici
SEShirit Einav
Shirit Einav
Severe dengue (SD) is a major cause of morbidity and mortality impacting approximately 5 million of the 400 million people infected with dengue virus (DENV) annually. To define DENV target cells and immunological hallmarks of SD progression in children’s blood, we integrated virus-inclusive single cell RNA-Seq 2 (viscRNA-Seq 2) with functional assays. Beyond myeloid cells, in natural infection, B cells harbor replicating DENV capable of infecting permissive cells. Alterations in cell type abundance, gene and protein expression and secretion, and cell-cell communications point towards increased migration and inflammation in SD progressors (SDp). Concurrently, antigen presenting cells from SDp demonstrate intact uptake, yet impaired interferon responses and antigen presentation, in part DENV-modulated. Increased activation, regulation, and exhaustion of effector responses and expansion of HLA-DR-expressing, possibly compensatory, adaptive-like NK cells also characterize SDp. These findings reveal DENV target cells in the human blood and provide insight into SD pathogenesis beyond antibody-mediated enhancement.

10 June 2024 in Immunology & Cell Biology
Verified
Journal Article
Open access
CCCurtis Cai
Curtis Cai
EKElizabeth Keoshkerian
Elizabeth Keoshkerian
KWKristof Wing
Kristof Wing
JSJerome Samir
Jerome Samir
MEManuel Effenberger
Manuel Effenberger
FLFabio Luciani
Fabio Luciani
CD8+ T cells recognizing their cognate antigen are typically recruited as a polyclonal population consisting of multiple clonotypes with varying T‐cell receptor (TCR) affinity to the target peptide–major histocompatibility complex (pMHC) complex. Advances in single‐cell sequencing have increased accessibility toward identifying TCRs with matched antigens. Here we present the discovery of a monoclonal CD8+ T‐cell population with specificity for a hepatitis C virus (HCV)–derived human leukocyte antigen (HLA) class I epitope (HLA‐B*07:02 GPRLGVRAT) which was isolated directly ex vivo from an individual with an episode of acutely resolved HCV infection. This population was absent before infection and underwent expansion and stable maintenance for at least 2 years after infection as measured by HLA‐multimer staining. Furthermore, the monoclonal clonotype was characterized by an unusually long dissociation time (half‐life = 794 s and koff = 5.73 × 10−4) for its target antigen when compared with previously published results. A comparison with related populations of HCV‐specific populations derived from the same individual and a second individual suggested that high‐affinity TCR–pMHC interactions may be inherent to epitope identity and shape the phenotype of responses which has implications for rational TCR selection and design in the age of personalized immunotherapies.